Market research
6MX.F Eidos Therapeutics, Inc
F EUR Healthcare
Latest close
Latest stored close unavailable
Test a moving-average rule with historical data.
Market facts
- Market cap
- 4B
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- -0.17
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 4B
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- -0.17
About
About Eidos Therapeutics, Inc
Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.
Research context
Eidos Therapeutics, Inc appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 6MX.F discussion.
5 years, 7 months ago
Eidos Therapeutics, Inc is currently in a long term uptrend where the price is trading 63.3% above its 200 day moving average.
From a valuation standpoint, the stock is 2614.5% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 35655.0.
Eidos Therapeutics, Inc's total revenue sank by 99.5% to $127K since the same quarter in the previous year.
Its net income has dropped by 535.4% to $-30M since the same quarter in the previous year.
Finally, its free cash flow fell by 355.0% to $-28M since the same quarter in the previous year.
Based on the above factors, Eidos Therapeutics, Inc gets an overall score of 1/5.